|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Dr. Randall C. Schatzman Ph.D.||CEO & Director||829.32k||N/D||1955|
|Dr. Edgar George Engleman M.D.||Founder & Independent Director||38.75k||N/D||1946|
|Mr. William P. Quinn||CFO & Secretary||594.56k||N/D||1971|
|Mr. Grant Yonehiro C.F.A., M.B.A.||Chief Business Officer||544.71k||N/D||1964|
|Dr. Edith A. Perez M.D.||Chief Medical Officer||668.32k||N/D||1957|
|Mr. Wesley Burwell||VP & Head of Human Resources||N/D||N/D||N/D|
|Dr. Nathan Ihle Ph.D.||Senior Vice President of Pharmaceutical Operations||N/D||N/D||N/D|
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
La calificación ISS Governance QuickScore de Bolt Biotherapeutics, Inc. a partir del 1 de diciembre de 2023 es 9. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 8; Compensación: 9.